A drug and drug delivery candidate technology, research into which has been funded by the National Foundation for Cancer Research (NFCR), has recently been approved by the U.S. Food and Drug Administration (FDA) for the initiation of human clinical trials.…
First of Its Kind Investment Competition for Female-Led Cancer-Focused Start-Ups ROCKVILLE, MD – The AIM-HI Accelerator Fund is organizing the first annual Women’s Venture Competition on May 20 in Boston. Applications are being accepted online until April 16 from oncology…
ROCKVILLE, MD – The co-founder and CEO of the AIM-HI Accelerator Fund will chair a panel conversation at an event coinciding with the annual JP Morgan Healthcare Conference. On Sunday, January 12, Sujuan Ba, Ph.D., will lead a morning discussion…
ROCKVILLE, MD – A portfolio start-up company of the AIM-HI Accelerator Fund has been awarded $700,000 from Virginia Catalyst to commercialize its lead cancer drug candidate. Richmond-based InterLeukin Combinatorial Therapies (ILCT) is developing unique engineered therapeutic interleukins (a type of…
